FDA Hopes Evaluations For Sinopharm COVID-19 Vaccine To Get EUA Will Be Completed Soon

The FDA expressed optimism that the evaluations for the Sinopharm COVID-19 vaccine to get EUA will be completed soon.

The Food and Drug Administration (FDA) expressed optimism that the evaluations for the Sinopharm COVID-19 vaccine to get an Emergency Use Authorization (EUA) will be completed soon.

FDA Sinopharm

During President Rodrigo Duterte’s “Talk to the People” on Thursday night, FDA Director-General Eric Domingo gave an update on the COVID-19 vaccines – particularly on those that can be used to vaccinate Filipinos in the future.

Domingo said that it’s possible for Sinopharm to get an EUA in the Philippines, noting that the officials of the Department of Health (DOH) – which applied for the emergency use authorization for the said vaccine brand – have already met with representatives of Sinopharm.

READ ALSO: WHO Lists Sinopharm COVID-19 Vaccine For Emergency Use

The Department of Health, under the orders of Health Secretary Francisco Duque III, filed an emergency use authorization (EUA) for Sinopharm COVID-19 vaccine. This was to ensure that the Philippines didn’t have to return a batch of the brand donated by China.

Domingo added that the FDA also sent to the country’s Vaccine Expert Panel (VEP) the “scientific data and clinical trial data of Sinopharm” last May 12 in order for them to check.

Meanwhile, Domingo noted that the Food and Drug Administration was also waiting for Novavax that would complete the national government’s vaccine portfolio.

Ang inaabangan natin na bakuna na lang ang Novavax na hopefully, by next month, baka bigyan din ng US or India yung kanilang EUA at para makapag-apply na din dito – makukumpleto na ang listahan ng bakuna na maari natin bilhin,” Domingo said.

For more news and updates, you may feel free to visit this site more often. You may also visit Newspapers.ph via our official Facebook page and YouTube channel.

Leave a Comment